DRI Capital Acquires Rights to Nanogen Royalties

Mar 31, 2008

NEW YORK (GenomeWeb News) – DRI Capital will pay Nanogen $10 million for the rights to all future royalties under a licensing agreement between Nanogen and Applied Biosystems.

According to a joint announcement from the firms, DRI Capital will receive royalties related to Nanogen’s minor groove binder technology, which was licensed by ABI for use in certain TaqMan products. The MGB technology is used for the design of oligonucleotide probes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Sharing, But Kinda Sorta

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

Structural Biologist Leads India's CSIR

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

Upward of One Hundred

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

This Week in Science

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Main menu